Mary Chris Jammet Joins the Boards of Directors of Adams Diversified Equity Fund and Adams Natural Resources Fund

PR Newswire

BALTIMORE, Dec. 10, 2020 /PRNewswire/ — The Boards of Directors of Adams Diversified Equity Fund (NYSE: ADX) and Adams Natural Resources Fund (NYSE: PEO), two of the nation’s oldest closed-end funds, announce the election of Mary Chris Jammet as an independent director of the Funds, effective December 10, 2020.

Ms. Jammet is a seasoned investment management professional and experienced corporate board member who brings more than 30 years of experience to Adams Funds.  Currently a Principal with Bristol Partners, Ms. Jammet served as Senior Vice President and Portfolio Manager at global asset management firm Legg Mason, Inc. (now Franklin Templeton), where she was responsible for $20 billion in client assets before retiring in 2013.  In 2014, Ms. Jammet was elected to the Board of Directors of MGM Resorts International (MGM).  Ms. Jammet is an Audit Committee Financial Expert and, in July 2020, she received a CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University’s Software Engineering Institute. Ms. Jammet is a former Corporate Director for Payless.  She currently serves as an Advisor to Loyola University Maryland’s Finance Department and is a member of the National Association of Corporate Directors, as well as the Women Corporate Directors Foundation.  Ms. Jammet received her undergraduate degree in Finance from Towson University and her graduate degree in Finance from Loyola University Maryland.

Mary Chris brings a wealth of experience in investment management to Adams Funds,” said Mark Stoeckle, CEO of the Funds. “We look forward to her insights and contributions.”

“I am honored and excited to join the Boards of Directors for Adams Funds,” said Ms. Jammet.  “Adams Funds has two of the most well-respected closed-end funds in the market today.  I am grateful for the opportunity to be a steward for these historic Funds and I look forward to working with the Boards and contributing to the Funds’ growth and success.”

###

Since 1929, Adams Funds has consistently helped generations of investors reach their investment goals. Adams Funds is comprised of two closed-end funds, Adams Diversified Equity Fund, Inc. (NYSE: ADX) and Adams Natural Resources Fund, Inc. (NYSE: PEO). The Funds are actively managed by an experienced team with a disciplined approach and have paid dividends for more than 80 years across many market cycles. The Funds are committed to paying an annual distribution rate of 6% or more, providing reliable income to long-term investors. Shares can be purchased through our transfer agent or through a broker. For more information about Adams Funds, please visit: adamsfunds.com.

Contact:

Lyn Walther

Director of Shareholder Communications
Adams Funds
410.752.5900 or 800.638.2479
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/mary-chris-jammet-joins-the-boards-of-directors-of-adams-diversified-equity-fund-and-adams-natural-resources-fund-301190807.html

SOURCE Adams Funds

Scientific Games Will Supply Lottery Instant Games, e-Instants And Latest Generation WAVE™ Retailer Technology For SISAL In Morocco

African Lottery Market a First for Company’s Rapidly Expanding Lottery Tech Business

PR Newswire

LAS VEGAS and ATLANTA, Dec. 10, 2020 /PRNewswire/ — Scientific Games Corporation (NASDAQ: SGMS) (“Scientific Games” or the “Company”) will supply and deploy lottery instant games, e-instant digital games, and WAVE lottery retailer terminals to SISAL S.p.A. (“SISAL”) in Morocco beginning this month. This represents a very important step in Scientific Games’ objective of dramatically growing its footprint in the rapidly developing African lottery market.

Scientific Games will provide e-instant games through an integration of its Open Gaming System, lottery instant scratch cards, and the Company’s latest generation WAVE retailer terminals to support SISAL in developing the national lottery of Morocco’s retailer network.

Pat McHugh, Lottery Group Chief Executive for Scientific Games, said, “We are honored by the continued trust that SISAL has placed in our ability to deliver a variety of value-added products and services that maximizes sales and proceeds for a number of their international lottery operations. We are particularly excited about supporting the national lottery in Morocco and deploying our games and technology in the African market.”

SISAL is one of Italy’s largest, most prominent and responsible gaming operators holding significant marketshare in the lottery, betting, AWP machines, video lottery and digital gaming sectors. Scientific Games supported SISAL in its preparation of the Moroccan national lottery bid of Societe de Gestion de la Loterie Nationale. In February 2018, SISAL was awarded the 10-year concession to operate the Moroccan lottery, which launched in January 2019.

Marco Caccavale, Managing Director of Lottery and International Business of SISAL, said, “We are extremely pleased to have been awarded the concession to operate the national lottery in Morocco. Most recently, we have enjoyed significant market successes with the award of the concession to operate parimutuel games (GNTN) in Italy, and winning the bid to operate the national lottery in Turkey with our partner Şans Dijital, an affiliate of Demirören Holding, one of Turkey’s largest companies. For all of these significant opportunities, Scientific Games offers relevant, innovative products and services for several growth segments of our businesses. The extent of the collaboration we have with Scientific Games in Morocco, Italy and Turkey is clear evidence of the strength of our strategic partnership.”

Scientific Games has provided lottery retail technology to SISAL since 1997, with SISAL relying on the Company for the vast majority of its retailer terminals in Italy. In 2017, Scientific Games and SISAL further strengthened their collaboration, entering into a strategic partnership agreement.

Currently the largest lottery technology provider in Europe and the fastest growing in the U.S., Scientific Games supplies games, technology and services to more than 150 lotteries in 50 countries, and sports betting solutions to 24 lotteries and numerous private operators. The Company is a responsible gaming supplier.

© 2020 Scientific Games Corporation. All Rights Reserved.

About Scientific Games 
Scientific Games Corporation (NASDAQ: SGMS) is a world leader in entertainment offering dynamic games, systems and services for casino, lottery, social gaming, online gaming and sports betting. Scientific Games offers the gaming industry’s broadest and most integrated portfolio of game content, advanced systems, cutting-edge platforms and professional services. Committed to responsible gaming, Scientific Games delivers what customers and players value most: trusted security, engaging entertainment content, operating efficiencies and innovative technology. For more information, please visit scientificgames.com

Media Inquiries: 
[email protected]  

Forward-Looking Statements 
In this press release, Scientific Games makes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “will,” “may,” and “should.” These statements are based upon management’s current expectations, assumptions and estimates and are not guarantees of timing, future results or performance. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors, including those factors described in our filings with the Securities and Exchange Commission (the “SEC”), including Scientific Games’ current reports on Form 8-K, quarterly reports on Form 10-Q and its latest annual report on Form 10-K filed with the SEC on February 18, 2020 (including under the headings “Forward-Looking Statements” and “Risk Factors”). Forward-looking statements speak only as of the date they are made and, except for Scientific Games’ ongoing obligations under the U.S. federal securities laws, Scientific Games undertakes no obligation to publicly update any forward-looking statements whether as a result of new information, future events or otherwise.  

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/scientific-games-will-supply-lottery-instant-games-e-instants-and-latest-generation-wave-retailer-technology-for-sisal-in-morocco-301190853.html

SOURCE Scientific Games Corporation

AMERCO Announces Special Cash Dividend

PR Newswire

RENO, Nev., Dec. 10, 2020 /PRNewswire/ — AMERCO (Nasdaq: UHAL), the parent of U-Haul International, Inc., Oxford Life Insurance Company, Repwest Insurance Company and Amerco Real Estate Company, on December 9, 2020, declared a special cash dividend on its Common Stock of $2.00 per share. The dividend will be payable December 30, 2020 to holders of record on December 21, 2020.

About AMERCO

AMERCO is the parent company of U-Haul International, Inc., Oxford Life Insurance Company, Repwest Insurance Company and Amerco Real Estate Company. U-Haul is in the shared use business and was founded on the fundamental philosophy that the division of use and specialization of ownership is good for both U-Haul customers and the environment.

About U-Haul

Since 1945, U-Haul has been the choice for the do-it-yourself mover. U-Haul customers’ patronage has enabled the Company to maintain the largest rental fleet in the do-it-yourself moving industry which includes a fleet of trucks, trailers and towing devices. U-Haul also offers storage throughout North America. U-Haul is the consumer’s number one choice as the largest installer of permanent trailer hitches in the automotive aftermarket industry. The Company supplies alternative-fuel for vehicles and backyard barbecues as one of the nation’s largest retailers of propane.

Cision View original content:http://www.prnewswire.com/news-releases/amerco-announces-special-cash-dividend-301190854.html

SOURCE AMERCO

McAfee Reports Quarterly Dividend for the Fourth Quarter 2020

McAfee Reports Quarterly Dividend for the Fourth Quarter 2020

SAN JOSE, Calif.–(BUSINESS WIRE)–
McAfee Corp. (“McAfee,” or the “Company”) (NASDAQ: MCFE) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2020 of $0.087 per share on the Company’s Class A common stock. The dividend is payable on or about January 7, 2021 to shareholders of record at 5:00 p.m. Eastern standard time on December 24, 2020.

About McAfee

McAfee is the device-to-cloud cybersecurity company. Inspired by the power of working together, McAfee creates consumer and business solutions that make the world a safer place.

McAfee® and the McAfee logo are trademarks of McAfee, LLC or its subsidiaries in the United States and other countries. Other marks and brands may be claimed as the property of others.

Investor Relations Contact:

Chris Mammone

[email protected]

Media Contact:

Jamie Le

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Internet Security Data Management Technology Software

MEDIA:

Logo
Logo

LINKBANCORP, Inc. and GNB Financial Services, Inc. Announce Strategic Combination

LINKBANCORP, Inc. and GNB Financial Services, Inc. Announce Strategic Combination

HARRISBURG, Pa.–(BUSINESS WIRE)–
LINKBANCORP, Inc. (OTC Pink: LNKB) and GNB Financial Services, Inc., (OTC Pink: GNBF) today announced the execution of a definitive agreement to combine in a stock and cash transaction, creating a leading Pennsylvania community bank with assets in excess of $800 million and a network of nine offices throughout South Central Pennsylvania.

Under the terms of the agreement, which has been unanimously approved by the boards of directors of both companies, GNB Financial Services will merge with and into LINKBANCORP, with LINKBANCORP surviving the merger. Shareholders of GNB Financial will have the opportunity to elect to receive $87.68 per share in cash or 7.3064 shares of LINKBANCORP common stock for each share they own, representing a total valuation of approximately $62.6 million based on the trading price of LINKBANCORP as of December 7, 2020. The agreement provides for proration procedures intended to ensure that, in the aggregate, at least 80 percent of the GNB Financial common shares outstanding will be exchanged for LINKBANCORP common stock. The transaction is expected to be a tax-free exchange to the extent shareholders of GNB Financial receive stock in exchange for their shares. LINKBANCORP shareholders will own approximately 52% and GNB Financial shareholders will own approximately 48% of the combined company.

“This is a true partnership, leveraging the strengths of each institution to create a community bank that is extremely well positioned for the future,” said LINKBANCORP Chief Executive Officer Andrew Samuel, who founded LINKBANCORP in 2018 and will serve as CEO of the combined company. “It’s a very attractive financial transaction that accelerates our growth plan and evidences our commitment to an entrepreneurial, values-driven community banking model that positively impacts all of our constituencies,” said Samuel.

The combined company’s board of directors will be evenly split between the two institutions, and will be chaired by Joseph C. Michetti, Jr., currently the Chairman of GNB Financial.

Wesley M. Weymers, Chief Executive Officer of GNB Financial, stated, “We have great respect for LINKBANK’s very experienced and talented team and what they have accomplished in a relatively short period. This partnership is an exciting opportunity to combine two very complementary institutions and achieve the scale and talent needed to compete and thrive in a rapidly evolving environment.”

The companies anticipate that the combination, uniting the rich and successful legacy of The Gratz Bank, which was founded in 1934, with the growth-oriented commercial bank model of LINKBANK, will result in significant earnings growth. Following the effective date of the combination, LINKBANCORP intends to pay a quarterly dividend consistent with the historical practice of GNB Financial, provided sufficient funds are legally available and that the surviving bank remains “well capitalized” in accordance with applicable regulatory guidelines.

Although the companies’ subsidiary banks, LINKBANK and The Gratz Bank, will merge immediately following the parent company merger, with The Gratz Bank as the surviving legal entity, both community-based institutions will continue operating under their established brands and their respective customers will receive the same high-level of services and products from the familiar faces at their existing locations. No branch locations are anticipated to close as a result of the combination.

Simultaneous with the agreement, Mr. Weymers entered into a new employment agreement pursuant to which he will serve as Executive Chairman of The Gratz Bank at the effective time of the combination, joining current GNB executives Jeremy Dobbin, Aaron Klinger and Kevin Laudenslager who will each assume senior management positions at the combined bank, and the existing LINKBANK executives who will maintain their current roles, to form a highly experienced leadership team, led by Mr. Samuel as Chief Executive Officer.

The parties expect to complete the transaction in mid-2021, after satisfaction of customary closing conditions, including required regulatory and shareholder approvals.

Cedar Hill Advisors LLC acted as financial advisor to LINKBANCORP, Inc. and Boenning & Scattergood, Inc. acted as financial advisor to GNB Financial Services, Inc. Hogan Lovells US LLP acted as legal counsel for LINKBANCORP, Inc. and Pillar + Aught acted as legal counsel for GNB Financial Services, Inc.

ABOUT LINKBANCORP, Inc.

LINKBANCORP, Inc. was formed in 2018 with a mission to positively impact lives through community banking. Its subsidiary bank, LINKBANK is a Pennsylvania state-chartered bank serving individuals, families, nonprofits and business clients throughout Central and Southeastern Pennsylvania. As of September 30, 2020, LINKBANK had total assets of approximately $368.6 million. LINKBANCORP, Inc. common stock is traded over the counter (OTC Pink) under the symbol “LNKB”.

ABOUT GNB FINANCIAL SERVICES, Inc.

GNB Financial Services, Inc. is the parent company of The Gratz Bank and GNB Investment Corp. Founded in 1934, The Gratz Bank is a full-service state chartered commercial bank, providing a variety of financial services to individual and commercial customers throughout Dauphin County, Pennsylvania, and other contiguous counties, through its main office located in Gratz, Pennsylvania, its branch offices in Valley View, Herndon, Pottsville, Minersville and Trevorton, Pennsylvania, and its loan production office in State College, Pennsylvania. As of September 30, 2020, GNB Financial services had total assets of approximately $437.1 million. GNB Financial Services common stock is traded over the counter (OTC Pink) under the symbol “GNBF”.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements about LINKBANCORP (together with its bank subsidiary unless the context otherwise requires, “LINK”) involve substantial risks and uncertainties. Statements other than statements of current or historical fact, including statements regarding LINK’s future financial condition, results of operations, business plans, liquidity, cash flows, projected costs, and the impact of any laws or regulations applicable to LINK, are forward-looking statements. Words such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “intends,” “plans,” “projects,” “may,” “will,” “should,” and other similar expressions are intended to identify these forward-looking statements. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. Among the risks and uncertainties that could cause actual results to differ from those described in the forward-looking statements include, but are not limited to the following: (1) the businesses of LINK and GNB Financial Services, Inc. (“GNB Financial”) may not be combined successfully, or such combination may take longer to accomplish than expected; (2) the cost savings from the merger may not be fully realized or may take longer to realize than expected; (3) operating costs, customer loss and business disruption following the merger, including adverse effects on relationships with employees, may be greater than expected; (4) governmental approvals of the merger may not be obtained, or adverse regulatory conditions may be imposed in connection with governmental approvals of the merger; (5) the stockholders of LINK or GNB Financial may fail to approve the merger; (6) changes to interest rates; (7) the ability to control costs and expenses; (8) general economic conditions; (9) adverse developments in borrower industries and, in particular, declines in real estate values; (10) LINK’s ability to maintain compliance with federal and state laws that regulate its business and capital levels; (11) LINK’s ability to raise capital as needed by its business; (12) the duration and scope of the coronavirus disease 2019 (“COVID-19”) pandemic and its impact on levels of consumer confidence; (13) actions governments, businesses and individuals take in response to the COVID-19 pandemic; (14) the impact of the COVID-19 pandemic and actions taken in response to the pandemic on global and regional economies and economic activity, and (15) the pace of recovery when the COVID-19 pandemic subsides. LINK does not undertake, and specifically disclaims any obligation, to publicly release the result of any revisions which may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. You are cautioned not to place undue reliance on these forward-looking statements.

Additional Information and Where to Find it

In connection with the proposed transaction, LINK expects to file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-4 that will include a joint proxy statement of LINK and GNB Financial that also constitutes a prospectus of LINK. INVESTORS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) at the SEC’s website at www.sec.gov. Copies of the documents filed by LINK with the SEC will be available free of charge on LINK’s website at ir.linkbancorp.com or by directing a request to LINKBANCORP, Inc., 3045 Market Street, Camp Hill, PA 17011, attention: Secretary.

Participants in Solicitation

LINK and GNB Financial and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about the directors and officers of LINK and GNB Financial and their ownership of LINK and GNB Financial common stock, and the interests of such potential participants will be included in the joint proxy statement/prospectus if and when it becomes available.

Andrew Samuel

LINKBANK

(717) 798-4230

[email protected]

Wesley M. Weymers

The Gratz Bank

(717) 508 4300

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products

WOODSTOCK, Ga.–(BUSINESS WIRE)–
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing high performance stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, oral care, nasal care and dermatological conditions, and Crown Laboratories, Inc., a fully integrated global skin care company, announce they have entered into a license and supply agreement for the exclusive rights to sell and market products for the over-the-counter (OTC) dermatological market in the United States. Crown plans to sell Sonoma’s Microcyn® technology dermal sprays and gels targeting itch and pain under Sarna®, the #1 Dermatologist Recommended Anti-Itch Brand, with a unique variety of formulations to quickly relieve itch and skin irritations.

Sonoma’s HOCl line of products are clinically proven to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. Sonoma will continue to sell its prescription strength products while Crown will distribute an OTC version available without prescription.

“Having access to Sonoma’s Microcyn® technology provides us with the first in class hypochlorous acid-based products in the OTC dermatology market. We believe that integrating these new products into our portfolio of strong brands will provide greater patient access and help improve patient outcomes,” said Jeff Bedard, Crown’s CEO.

“Crown is committed to providing safe and effective solutions that relieve discomfort associated with compromised skin,” said Steve Gallopo, Crown’s Vice President, US/Global OTC Marketing. “Managing pruritus (itch) is essential as it is a major symptom associated with many skin ailments. We are thrilled to offer a clinically proven, steroid-free line of HOCl-products within the Sarna franchise as this represents a major advancement in combating itch within the OTC market.”

“We are excited to partner with Crown Laboratories, which shares our passion of providing patients with access to highly effective health care products. In addition, Crown has extensive experience selling in OTC markets and this partnership will expand our OTC offerings to consumers across the United States and into online retail markets,” said Amy Trombly, Sonoma’s CEO.

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 53 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact [email protected].

About Crown Laboratories

Crown, a privately held, fully integrated global skin care company, is committed to developing and providing a diverse portfolio of aesthetic, beauty, and therapeutic skin care products that improve the quality of life for its customers. An innovative company focused on skin science for life, Crown’s unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it is poised to become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for seven years and has expanded its distribution to over 38 countries. For more information about Crown or its products, visit www.crownlaboratories.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “advance,” “develop” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:

Sonoma Pharmaceuticals, Inc.

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Health FDA Other Health General Health Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants

HAYWARD, Calif.–(BUSINESS WIRE)–
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted twenty new employees options to purchase a total of 310,500 shares of the Company’s common stock at an exercise price per share of $29.93, which was the closing price on December 8, 2020. The stock options were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab and AB154 plus AB928 with zimberelimab. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, and in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences

Katherine Bock

VP Investor Relations & Corporate Strategy

(510) 694-6231

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Kinsale Capital Group Announces the Appointment of Two New Board Members

RICHMOND, Va., Dec. 10, 2020 (GLOBE NEWSWIRE) — Kinsale Capital Group, Inc. (Nasdaq: KNSL) today announced the appointment of two new members to its Board of Directors, effective January 1, 2021. Joining the board are Teresa P. Chia and Robert (Trey) V. Hatcher, III. These appointments increase Kinsale’s total board membership from seven to nine.

“We are delighted to welcome Teresa and Trey to Kinsale’s board, and together they bring extensive leadership and industry expertise,” said Robert Lippincott III, Chairman of the Board of Directors at Kinsale. “The diverse backgrounds of Teresa and Trey complement our existing board of directors’ skills and experience, and we are confident they will provide valuable perspectives. We look forward to their contributions as we continue to execute our strategy, drive profitability and enhance value for all our stakeholders.”

Ms. Chia currently serves as a Managing Director at White Mountains Capital LLC, a subsidiary of White Mountains Insurance Group, Ltd. where she focuses on the company’s direct investing and merger and acquisition activity in the insurance and financial services sectors. Prior to joining White Mountains in 2013, Ms. Chia was an investment professional at Permira Advisers LLC, a global investment firm, from 2009 to 2013. Prior to joining Permira, Ms. Chia served as an investment professional at Nautic Partners, LLC, a middle-market private equity firm, and in investment banking at Credit Suisse. Ms. Chia received a B.A. in Economics from Wellesley College and an M.B.A. from Harvard Business School.

Mr. Hatcher has more than 40 years of insurance industry experience and has served as Vice Chairman of Willis Re Inc., a reinsurance division of Willis Towers Watson plc, a position he has held since January 2018. At Willis Re Inc., Mr. Hatcher previously served as Executive Vice President from April 2006 to December 2017 and as Senior Vice President from January 1994 to April 2006. Prior to joining Willis Re Inc., Mr. Hatcher held positions of increasing responsibility at Towers Perrin Reinsurance, Willis Faber Ltd. and Chubb & Son Inc. Mr. Hatcher received a B.A. in Economics from Hampden-Sydney College.

About Kinsale Capital Group
, Inc.

Kinsale Capital Group, Inc. is a specialty insurance group headquartered in Richmond, Virginia, focusing on the excess and surplus lines market.

Contact

Bryan Petrucelli
Executive Vice President, Chief Financial Officer and Treasurer
(804) 289-1272
[email protected] 



NCSBN Launches Research Study to Investigate Prelicensure RN Education During the Pandemic

Chicago, Dec. 10, 2020 (GLOBE NEWSWIRE) — NCSBN has launched a new research study, “National Prelicensure RN Study: Assessing the Impact of COVID-19 on Nursing Education,” to investigate the impact of the rapid changes being made in nursing education programs in response to the COVID-19 pandemic.

 

Principal Investigator Brendan Martin, PhD, director, NCSBN Research, notes, “NCSBN undertook this study to explore the many ways in which nursing programs were able to quickly adapt to the conditions brought about by the pandemic, but even more importantly to discover how changes in instructional/clinical models will affect nursing student performance and eventual readiness to practice.”

 

The study, which is currently underway at more than 50 nursing program sites across the nation, seeks to determine the extent to which prelicensure RN programs, either traditional Bachelor of Science in Nursing (BSN) or Associate Degree in Nursing (ADN), changed their didactic and/or clinical delivery formats due to the COVID-19 pandemic. The study will then prospectively and longitudinally track student outcomes to measure engagement, academic performance, and early career experience.

 

“The key strengths of this study will be its early efforts to track student performance in real-time during the COVID-19 pandemic and, from a regulatory standpoint, its focus on how well these experiences prepare new graduates for their transition to early career professionals,” adds Martin. 

 

The study will conclude in 2022. For more information contact the study lead, Brendan Martin, at [email protected].

 

About NCSBN

 

Founded March 15, 1978, as an independent not-for-profit organization, NCSBN was initially created to lessen the burdens of state governments and bring together nursing regulatory bodies (NRBs) to act and counsel together on matters of common interest. It has evolved into one of the leading voices of regulation across the world.

 

NCSBN’s membership is comprised of the NRBs in the 50 states, the District of Columbia, and four U.S. territories — American Samoa, Guam, Northern Mariana Islands and the Virgin Islands. There are three exam user members. There are also 27 associate members that are either NRBs or empowered regulatory authorities from other countries or territories.

 

Mission: NCSBN empowers and supports nursing regulators in their mandate to protect the public.

 

The statements and opinions expressed are those of NCSBN and not individual members.

 

######



Dawn Kappel
NCSBN
3122182418
[email protected]

IIROC Trade Resumption – EATS

Canada NewsWire

VANCOUVER, BC, Dec. 10, 2020 /CNW/ – Trading resumes in:

Company: Eat Beyond Global Holdings Inc.

CSE Symbol: EATS

All Issues: No

Resumption (ET): 3:31:21 PM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC)